The PR in my post said that "While significant progress in Discovery's manufacturing investigation and remediation has been made, the investigation is ongoing and when completed, Discovery intends to finalize a comprehensive investigation report and corrective action plan." I guess us peons aren't going to be privy to it.
The same PR noted that . . . "In December 2005 Discovery acquired and took control of the Totowa, NJ manufacturing operations of Laureate Pharma, Inc. Concurrently, pharmaceutical executives with extensive manufacturing, regulatory, and quality assurance expertise joined Discovery's senior management team. The expertise of these executives coupled with the remediation outcomes is expected to enhance pharmaceutical development across Discovery's broad SRT product pipeline."
discoverylabs.com
Said execs weren't from Laureate, thank goodness, because Laureate was DSCO's contract manufacturer, and Surfaxin manufacturing was basically all that plant did.
Then there's Miljenko's comment:
Message 22813755
I always respect his opinions, and I believe he has something to do with drug manufacturing in real life, so I especially respect his opinions on that.
So have the new guys straightened everything out? I'd like to think so, and might even take a small position if the stock acts well (stock price seems to be a good indicator these days; see PANC and NFLD charts before the bad news came out for them). But for a larger position, I think I'll be a little late to the party, should there be one. DSCO probably still has options, though I haven't looked. IV is another indicator.
Cheers, Tuck |
